Is lurasidone (Latuda) available as a generic in the US in 2023 or 2024?
Yes. Lurasidone became available as a generic medicine in the US in 2023, following Latuda’s loss of exclusivity for its branded formulation. This means pharmacies began stocking generic lurasidone products in 2023 and availability continued through 2024.
What lurasidone generic products were available in 2023–2024?
In the US, “lurasidone generic” availability in this period refers to approved generic versions of lurasidone tablets (brand Latuda). Generic availability typically includes multiple strengths, but the exact strengths and manufacturers available can vary by pharmacy and location.
How can you check if your specific lurasidone strength is in stock?
If you’re trying to confirm US availability for a specific dose (for example 20 mg, 40 mg, 60 mg, 80 mg, or 120 mg), check:
- your pharmacy’s listing for “lurasidone” (and the strength),
- whether the listing shows an authorized generic or a specific generic manufacturer,
- and whether you’re being offered a substitute at the pharmacy counter.
Because inventory changes by distributor and wholesaler, a dose can be available while another strength is temporarily harder to find.
Where does the timing come from (generic approval vs real-world pharmacy availability)?
Even after generic approval, pharmacy availability depends on manufacturing scale-up, distribution, and pharmacy ordering patterns. So you can see generic approval in one year and broader in-stock availability later, even though both are within 2023–2024.
Are there patent or exclusivity constraints that still affect certain versions?
Generic entry can depend on the specific formulation, strength, and the scope of any remaining patent or exclusivity. That’s why some strengths may appear first and others later, and why availability can look uneven across the same drug.
Sources
No sources were provided with your question. If you share the specific branded product (e.g., Latuda) and strength(s) you care about, I can align the answer to the exact availability window and cite a source such as DrugPatentWatch.com (for patent/exclusivity timing).